AlphAIalphai — Financial news for AI agents
tickerreport.comJUN 13 min read$DRTS

Alpha Tau Medical (NASDAQ:DRTS) Sees Large Volume Increase – Here’s What Happened

Alpha Tau Medical (NASDAQ:DRTS) traded 527,329 shares on Monday, up 8% from the prior session, after last trading at $10.04 (previous close $10.83). Analysts cited include Citigroup raising its target to $9 (buy) and Barclays starting at $15 (overweight). The company reported EPS of -$0.26 on May 18, missing consensus (-$0.13).

Original reporting
tickerreport.com
Published Jun 1, 2026, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 4:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Alpha Tau Medical (NASDAQ:DRTS) Sees Large Volume Increase – Here’s What Happened — source image
Source · tickerreport.com
Decision brief

The 30-second read

$DRTSNeutralMed
01

Why it matters

The combination of an earnings miss, elevated trading volume, and mixed analyst stance (some higher targets, consensus Hold) increases the probability of continued short-term volatility and re-pricing of expectations.

02

Market read

Traders get a near-term tape/positioning signal (volume) plus a fundamental anchor (earnings miss) and incremental sentiment shifts (analyst target changes).

03

What to watch

The article highlights multiple price targets but doesn’t quantify changes in model assumptions or upcoming trial readouts; traders may overreact to target numbers without new clinical data.

Relevance 8/10Novelty 6/10Timing: today’s session: unusually strong volume (+8%) with the stock last at $10.04

Background

DRTS is a medical technology company developing targeted alpha-radiation therapies (DaRT) for solid tumors; it last reported quarterly results on May 18.

Company-level read

Ticker impact

$DRTSNeutralMedium confidence
Context

Alpha Tau Medical (DRTS) saw unusual volume and a recent earnings miss, alongside multiple analyst target/rating changes that can move sentiment.

Expected impact

Near-term volatility likely; direction depends on whether traders anchor to the earnings miss ($0.26 vs -$0.13 consensus) or to the higher analyst targets.

Evidence & confidence

It provides a concrete datapoint (earnings miss) and a measurable tape event (volume +8%), plus several explicit target changes, but no new clinical/regulatory event.

Market effects

Sector

Limited direct read-across; targeted alpha-radiation therapy names may see sentiment spillover from analyst revisions, but no sector-wide catalyst is cited.

Regional

Israel-headquartered biotech/medtech sentiment may be marginally supported by Wall Street coverage changes; no regional policy or supply-chain issue mentioned.

Global

No global deal/regulatory development; relevance is primarily company-specific.

Counterpoint

What could challenge this read

The volume spike could be positioning around already-known post-earnings weakness rather than a new fundamental catalyst; consensus remains Hold.

Key entities

  • company
    Alpha Tau Medical Ltd.

    NASDAQ-listed targeted alpha-radiation therapy developer; subject of the volume/earnings/analyst-target updates.

  • analyst_firm
    Citigroup

    Raised its DRTS price target to $9 and reiterated Buy.

  • analyst_firm
    HC Wainwright

    Reaffirmed Buy with a $15 target.

  • analyst_firm
    Zacks Research

    Raised rating from strong sell to hold.

  • analyst_firm
    Piper Sandler

    Raised target to $8 but kept Neutral.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min